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Abstract
Objective: To develop and validate a comprehensive patient-reported outcomes instrument focusing on the
impact of dry eye on everyday life (IDEEL).
Methods: Development and validation of the IDEEL occurred in four phases: 1) focus groups with 45 dry eye
patients to develop a draft instrument, 2) item generation, 3) pilot study to assess content validity in 16 patients
and 4) psychometric validation in 210 subjects: 130 with non-Sjögren’s keratoconjunctivitis sicca, 32 with Sjögren’s
syndrome and 48 controls, and subsequent item reduction.
Results: Focus groups identified symptoms and the associated bother, the impact of dry eye on daily life and the
patients’ satisfaction with their treatment as the central concepts in patients’ experience of dry eye. Qualitative
analysis indicated that saturation was achieved for these concepts and yielded an initial 112-item draft instrument.
Patients understood the questionnaire and found the items to be relevant indicating content validity. Patient input,
item descriptive statistics and factor analysis identified 55 items that could be deleted. The final 57-item IDEEL
assesses dry eye impact constituting 3 modules: dry eye symptom-bother, dry eye impact on daily life comprising
impact on daily activities, emotional impact, impact on work, and dry eye treatment satisfaction comprising
satisfaction with treatment effectiveness and treatment-related bother/inconvenience. The psychometric analysis
results indicated that the IDEEL met the criteria for item discriminant validity, internal consistency reliability, test-
retest reliability and floor/ceiling effects. As expected, the correlations between IDEEL and the Dry Eye
Questionnaire (a habitual symptom questionnaire) were higher than between IDEEL and Short-Form-36 and
EuroQoL-5D, indicating concurrent validity.
Conclusion: The IDEEL is a reliable, valid and comprehensive questionnaire relevant to issues that are specific to
dry eye patients, and meets current FDA patient-reported outcomes guidelines. The use of this questionnaire will
provide assessment of the impact of dry eye on patient dry eye-related quality of life, impact of treatment on
patient outcomes in clinical trials, and may aid in treatment effectiveness evaluation.
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T h eD r yE y eW o r k s h o pd e f i n e dd r ye y ea sa“multifac-
torial disease of the tears and ocular surface that results
in symptoms of discomfort, visual disturbance, and tear
film instability with potential damage to the ocular sur-
face” [1,2]. It is accompanied by detrimental effects on
patients’ health-related quality of life (HRQL) [3-6] and
vision-related quality of life [7]. Dry eye or non-Sjög-
ren’s keratoconjunctivitis sicca (non-SS KCS) is a condi-
tion due to lacrimal and/or meibomian gland
dysfunction leading to diminished production or
increased evaporation of tears [1,8]. It may be associated
with Sjögren’s Syndrome (SS), which is a systemic auto-
immune disorder in which chronic inflammation of the
lacrimal and salivary glands, that eventually leads to
insufficient tear production, and the characteristic clini-
cal features of dry eyes and dry mouth [1,9,10]. There
are two basic forms of SS [1,11]: primary SS, the disease
by itself that is not associated with any other illness, and
secondary SS, that develops in the presence of another
autoimmune disease such as rheumatoid arthritis, lupus
or psoriasis [1,11,12]. In susceptible individuals, exacer-
bating factors such as systemic medications that
decrease tear production or environmental conditions
that increase tear evaporation may lead to an increase in
the severity of symptoms. Thus, dry eye is a chronic
condition that is heterogeneous not only in aetiology,
but also in severity.
Multiple studies have shown that clinical tests can be
poorly associated with the changes in symptoms as the
disease progresses and the self-perceived severity of the
condition [13-18], although recent studies have shown
higher correlations with tear osmolarity [18] Other con-
ditions such as allergy, basement membrane disease or
conjuntivochalasis could present as dry eye, with symp-
toms of ocular irritation. Thus, a validated questionnaire
that fully assesses symptoms together with the effect of
dry eye on daily life is indicated [4,19,20].
Because dry eye symptoms can occur without clinical
signs of tissue damage, it has been considered a symp-
tom-based condition, especially in mild to moderate
cases[1,21]. It is often under-diagnosed relative to the
patients’ assessment [17], particularly among the elderly
and women. An incidence study in the elderly showed a
21.6% increase in dry eye over a ten-year period, which
increased with age and was greater in women [22].
However, patients with clear signs of dry eye may report
few symptoms, perhaps due to sensory damage of the
ocular surface. Thus, refining patient reported outcomes
to track the natural history of the condition, its variabil-
ity and its effect on daily life becomes critical [18].
Some of the common treatment methods for SS
include artificial tears, anti-inflammatory drugs, and
balanced diet and exercise to overcome pain and fatigue
[23,24]. Treatment of non-SS KCS is generally confined
to tear film replenishment and stabilization through use
of artificial tears, gels and ointments, ergonomic modifi-
cations and punctual occlusion [23]. In moderate to
severe non-SS KCS, patients report treatments to be of
limited value [13], and often become frustrated with
their treatment course, are forced to repeatedly visit
doctors and specialists, and ultimately seek alternative
treatments [25].
Multiple dry eye-specific questionnaires exist that aim
to assess frequency and severity of the dry eye symp-
toms or to help in dry eye diagnosis and screening
[13-16,26-30]. While the Ocular Surface Disease Index
(OSDI) addresses the impact of dry eye on vision-related
functioning and dry eye symptoms in terms of severity,
it covers only some of these aspects and is therefore
unlikely to describe the full impact and burden of dry
eye and its treatment on patients’ everyday life [6]. Only
the IDEEL covers all relevant domains of dry eye includ-
ing dry eye symptoms and dry eye-related quality of life
domains of the patients’ life that might be impacted (i.e.
visual functioning activities, psychological, social and
cognitive aspects), as well as treatment satisfaction
[4,19,20,31,32].
The purpose of this study was to develop and validate
a comprehensive patient-reported outcomes (PRO)
instrument, the Impact of Dry Eye on Everyday Life
(IDEEL) that extensively evaluates dry eye symptoms
and all the aspects of patients’ daily life impacted by the
condition and its treatment.
Methods
Dry eye expert clinicians
Dry eye expert clinicians on the team provided expertise
and took part extensively in the decisions throughout
the process of development and finalisation of the ques-
tionnaire. They gave their approval at each of the mile-
stones of the development and finalisation process. The
questionnaire was also reviewed and agreed by the clini-
cal investigators.
Development of the questionnaire
Phase 1: Patient focus groups
Six focus groups were conducted in the United States
(Alabama, California, Indiana and Minnesota) and
Canada (Toronto and Waterloo) with non-SS KCS (four
groups) and SS (two groups) subjects. Patients were
recruited in hospital-based clinics and private practices.
Clinical investigators at each study site recruited sub-
jects using the International Classification of Diseases,
Ninth revision, Clinical Modification (ICD-9CM) for the
non-SS KCS subjects and the San Diego criteria for SS
subjects (which includes a positive salivary gland biopsy)
[33]. To be eligible, subjects had to be aged over 18
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four weeks; they were excluded if they had a punctual
occlusion within the past 60 days or if they had experi-
enced a change in systemic medication regimen within
the last 30 days. Subjects signed consent forms prior to
study participation and were compensated for their
time. The focus groups were performed by trained mod-
erators using an interview guide specifically designed for
the purpose to help moderators lead the discussions,
and to ensure conformity across focus groups. Focus
groups were recorded and subsequently transcribed
verbatim.
Qualitative analysis of transcripts was performed using
methods derived from Grounded Theory, with patients’
quotes coded and organized into themes or concepts
[34]. Analysis was performed using Atlas.ti software ver-
sion 6.2 [35]. To verify adequate sample size and the
full coverage of the research topic, saturation was stu-
died. Saturation is defined as the point at which no new
concepts or information emerge with the addition of
more patient data [36-38]. Saturation was determined by
following concepts and information that arose per focus
groups ranked in the chronological order they were
conducted.
Phase 2: Concept elicitation and item generation
Using grounded theory methods, concepts and sub-con-
cepts were elicited from the analysis of transcripts. All
concepts and sub-concepts mentioned by subjects and
related to symptoms, daily impact, or treatment satisfac-
tion bother/convenience were included in a comprehen-
sive set of items that were generated to develop the
initial version of the questionnaire.
Phase 3: Pilot study/Cognitive debriefing
The feasibility of the pilot version of the questionnaire
was subsequently tested in dry eye subjects in the US
and Canada in an individual interview setting. Half of
the subjects in this phase had been involved in the focus
groups and the remaining half was recruited using the
same method as in Phase 1. Subjects completed the
pilot version and were questioned regarding their gen-
eral impressions of the questionnaire; its comprehen-
siveness; the clarity of the instructions, items and
response choices; and their interpretations and opinions
of the relevance of each question. Subjects were also
asked to provide suggestions on how to reword the
instructions, questions and response options.
Finalisation, scoring and psychometric validation of the
questionnaire
Study population and design
To participate in the psychometric validation study [13],
outpatients subjects had to be at least 18 years old,
must have had an eye exam in the past 18 months, and
a confirmed diagnosis of either non-SS KCS or SS
(except for the controls). Five optometrists and one
ophthalmologist participated as clinical investigators at
six study sites. ICD-9CM codes and the San Diego cri-
teria (which includes a positive salivary gland biopsy)
were used to identify non-SS KCS and SS subjects,
respectively [33]. Potential study subjects were screened
by the investigators by telephone, with a series of ques-
tions that ensured the presence of dry eye symptoms in
the previous 4 weeks; patients were excluded if they
wore contact lenses, had undergone refractive surgery,
had a punctual occlusion within the past 60 days, or
had experienced a change in systemic medication regi-
men within the past 30 days. Control subjects were
recruited from lists of patients who did not have ICD-
9CM diagnostic codes for dry eye. During the telephone
screening, these subjects had to have responded nega-
tively to the question, “Do you think you have dry eye?”
and that they have “never” or “rarely” had dry eye symp-
toms or used artificial tears. Finally, at least two thirds
of the control subjects recruited had to be older than 35
years to ensure the control population characteristics
were as close as possible as the ones of the patients.
Subjects also had to be literate in English, willing and
able to complete a series of questionnaires twice over a
two-week period and willing to undergo clinical testing
for dry eye as part of the study. Consent forms were
signed by all the subjects prior to study participation
and they were all compensated for their time.
Eligible patients underwent two visits: a baseline visit
and a second visit 2 weeks later. Informed consent was
obtained from subjects at the baseline visit [13].
Patient-reported outcome questionnaires and clinical
tests
The subjects completed the following questionnaires at
baseline and two weeks later, in the following order: the
pilot version of the IDEEL questionnaire, the Medical
Outcomes Study Short-Form-36 Health Survey (SF-36) a
36-item general measure of health status [39], the
revised Dry Eye Questionnaire (DEQ 2001) [27,39,40]
and the EuroQoL (EQ-5D), a 5-item general utility mea-
sure of health attributes [41]. The DEQ 2001 is a revi-
sion of the earlier DEQ questionnaire, which was
validated in a large unselected clinical population and
against dry eye diagnosis [27,40]. Subjects also com-
pleted a demographic form at the first visit and the Dry
Eye Change Scale, a 3-item change questionnaire that
assesses change in overall dry eye symptom status, at
the second visit.
To try to assess whether there was a relationship
between these clinical measures and the PROs measures,
the following clinical tests were performed by the inves-
tigators during the first visit: Snellen visual acuity, Schir-
mer 1 tear test, fluorescein tear break-up time, corneal
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staining.
Psychometric Analysis
Construct validity
The percentages of subjects from the total study popula-
tion who chose response options “not applicable” or
“none of the time” to the IDEEL items at baseline were
reviewed: items with percentages greater than 70% were
considered for deletion, as were items with high levels
of missing data (> 20%).
Principal components analysis (PCA) with promax
rotation analysis aided in the development of item-
dimension structures and item reduction of the pilot
version of the IDEEL [42]. Factors were retained when
eigenvalue was greater than 1 [42]. A threshold for fac-
tor loading of 0.40 was fixed for the PCA: items that did
not load well (≤ 0.40) with their own factor and items
that loaded > 0.40 on more than one factor were consid-
ered for deletion [43]. To be included in the factor ana-
lysis, subjects had to have completed all items in each
scale. If patients in the focus groups and content validity
indicated an item was important and expert clinicians
also endorsed the item as relevant to dry eye, the item
was retained regardless of statistical results.
Multi-trait Analysis was also performed to determine
the correlation between each item and the dimension to
which it belonged [43]. The analysis was performed
twice: before and after item reduction. As with the PCA
step, an item was considered for deletion if it did not
correlate with its own dimension at ≥ 0.40 (item conver-
gent validity) or if it correlated higher with a dimension
other than its own (item discriminant validity) [43].
Floor and ceiling effects were also investigated for each
of the items.
The following properties were assessed on the final
version of the IDEEL, after item reduction, finalisation
and scoring.
Reliability
Internal consistency reliability and reproducibility (’test-
retest reliability’) were examined. A Cronbach’sa l p h a
coefficient of ≥ 0.70 was considered acceptable for inter-
nal consistency [44]. Test-retest reliability was evaluated
by examining the Interclass Correlation Coefficients
(ICCs) between visit one (week 0) and visit two (week 2)
for patients who reported stability in their dry eye symp-
toms in the previous 2 weeks. An ICC of ≥ 0.70 was
considered acceptable for test-retest reliability [45].
Concurrent validity
Correlations (Pearson coefficients) between the general
health measures (SF-36, EQ-5D) and the specific ques-
tionnaire DEQ were studied and compared to similar
dimensions (i.e. covering a same concept) in the IDEEL.
Concurrent validity was supported if similar dimensions
or items in the SF-36, EQ-5D and DEQ were substan-
tially correlated (r ≥ 0.40) with the IDEEL [46].
Known group validity
Known group validity was assessed by examining differ-
ences in IDEEL baseline scores for groups of patients
with different levels of dry eye severity for each severity
assessment method. Three types of severity assessments
were made during the study: diagnosis severity of the
patients recruited (i.e. control, non-SS KCS or SS), clini-
cian report of severity and patient self-report of severity.
Clinical validity
The correlation between the IDEEL and clinical tests
previously listed was examined to assess clinical validity.
Statistical analyses were conducted using Statistical
Analysis Software version 8.2 and Multi-trait Analysis
Program - Revised software version 1.0 [43]. Analyses
were conducted using parametric tests. For all tests, a
significance level of 0.05 (two-sided) was used unless
otherwise indicated. When reducing the number of
items in the questionnaire, both statistical results and
the clinical relevance of items were considered prior to
deletion.
Conceptual framework
Following PCA and Multi-trait analysis findings, the
final conceptual framework of the questionnaire was
developed with input from clinical experts, and based
on the importance of the concepts and sub-concepts
from patients’ perspective.
Results
Development of the questionnaire
The focus groups had 6 to 10 participants in each; the
total population consisted of 45 patients: 30 with non-
SS KCS and 15 with SS. Age ranged from 20 to 79 years
(mean age = 58 ± 14 years). The majority of the patients
were female (91%), Caucasian (85%), with at least a high
school diploma or General Educational Development
(GED) diploma (86%). Time since dry eye diagnosis ran-
ged from 5 months to 25 years. Ninety percent of the
patients self-rated the severity of their dry eye as mild/
moderate (58%) or severe (32%). High blood pressure
and arthritis were the health conditions other than dry
eye most frequently experienced by subjects (22% and
20%, respectively).
The following concepts and sub-concepts emerged
from the focus group analysis as relevant to patients
experience with dry eye: vision-related symptoms and
their bothersomeness, including burning/heat sensations,
dryness/irritation, moisture-related symptoms, pain-
related symptoms, tired eyes, eye appearance, swelling,
tearing, light/wind sensitivity; daily life impact, including
physical, daily activities, work, relationships, cognitive,
emotions, leisure and social impact, visual-aid impact,
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impacts; and treatment experiences and satisfaction in
terms of inconvenience, effectiveness and frequency.
Saturation was achieved for dry eye symptoms and
these symptom sub-concepts, as well as for all of the
overarching concepts of dry eye daily life impact and for
the aforementioned sub-concepts.
Concepts and sub-concepts were selected that were
clinically important (as discussed with the dry eye expert
clinicians) and also important from a patient’s perspec-
tive (as emerged from the focus group discussions). An
initial 116-item questionnaire was developed that was
organized around the following modules: dry eye symp-
tom-bother (37 items); dry eye impact on daily life,
including impact on daily activities (21 items), emotional
impact due to dry eye (32 items), impact on work due to
dry eye (8 items); satisfaction with overall treatment (9
items) and satisfaction with eye drops (9 items). The
items were generated in US English.
The questionnaire was subsequently comprehension
tested in 16 subjects (mean age: 63 years; range: 41-79
years). The subjects were mainly female (81%), Cauca-
sian (87%) and had at least a high school diploma or
equivalent (94%). The 116-item questionnaire was com-
pleted in 18.5 minutes on average (range: 11-35 min-
utes). Overall, subjects expressed positive comments
regarding the questionnaire. Based on their reported
levels of understanding and their suggestions, minor
wording changes were made to the instructions and
questions. In total, two questions were removed, four
sets of questions were combined and three questions
were split into six questions, yielding 112 questions and
six hypothesised dimensions as described above. This
questionnaire was then fielded in the psychometric vali-
dation study.
Psychometric validation
Study population demographics
The demographics of the validation study subjects are
presented in Table 1. The population included 210 adult
subjects: 130 with non-SS KCS, 32 with SS, and 48 con-
trols. The majority of the population was Caucasian
female and the mean age was 51 years (range: 20-89
years). Follow-up pairwise t-tests showed that the group
of controls was significantly younger (39 years) than both
the non-SS KCS (55 years) and SS groups (58 years); the
latter two groups did not differ statistically by age.
Item Reduction, descriptive statistics and construct
validity
Given that dry eye symptom-bother, dry eye impact on
daily life and dry eye treatment satisfaction are concep-
tually distinct, it was hypothesised that each module
could be processed as single distinct sub-questionnaire
[47-49]. PCA was thus conducted on each of these mod-
ules separately. The impact on work due to dry eye
dimension was both included and excluded from factor
analyses due to smaller sample sizes for the work-related
items. The analyses mentioned below were conducted
on the total study population (n = 210).
F o rt h eD r yE y eI m p a c to nD a i l yL i f em o d u l e ,t h e
eigenvalues obtained with the PCA for the Impact on
Daily Activities and Emotional Impact due to Dry Eye
dimensions confirmed two distinct dimensions, with
eigenvalues > 1. For the Impact on Work Scale, the
eigenvalues suggested one dimension. Four items did
not load on any of the factors, and were retained as
individual items for conceptual reasons (i.e. items of
importance for the patients and/or expert clinicians;
these items were about wearing contact lenses, wearing
make-up, flying on an airplane and feeling helpless
about dry eye). The Dry Eye Symptom-Bother module
yielded a single factor, indicating a single dimension.
The eigenvalues for the Treatment Satisfaction module
suggested two dimensions: Satisfaction with Treatment
Effectiveness and Treatment-Related Bother/Inconveni-
ence. Two items did not load on any of the factors, and
were retained as individual items for conceptual reasons
(items about treatment frequency).
Only the Dry Eye Treatment Satisfaction module
showed a floor effect, which was low (5.84% for the
Table 1 Demographic characteristics of the psychometric
validation study population (n = 210)
Characteristics Control
(n = 48)
Non-SS KCS*
(n = 130)
SS*
(n = 32)
Sex (n (%))
Male 13 (27) 27 (21) 3 (9)
Female 35 (73) 103 (79) 29 (91)
Age (Year)
Mean 39.2 55.2 58.3
Standard deviation 11.8 15.3 11.8
Range 20.0-66.0 22.0-89.0 34.0-80.0
Ethnicity (n (%))
Caucasian 34 (71) 106 (82) 31 (97)
African-American 6 (13) 12 (9) 1 (3)
Hispanic/Spanish-American 5 (10) 5 (4) 0 (0)
Asian/Oriental/Pacific Islands 1 (2) 6 (5) 0 (0)
Other 2 (4) 1 (1) 0 (0)
Highest level of education (n (%))
High school diploma or less 9 (19) 23 (18) 6 (19)
Some college 13 (27) 47 (36) 8 (25)
College degree 15 (31) 29 (22) 11 (34)
Graduate/postgraduate 8 (17) 31 (24) 5 (16)
Other 3 (6) 0 (0) 2 (6)
* Non-SS KCS, Non Sjögren keratoconjunctivitis sicca; SS, Sjögren Syndrome
[13]
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IDEEL modules with the exception of the Dry Eye
Symptom-Bother module (0.6%). Acceptable ceiling
effects were evident for the remaining dimensions
(14.9% for Impact on Daily Activities, 13.7% for Emo-
tional Impact due to Dry Eye for those who were work-
ing, 13.4% for Impact on Work due to Dry Eye and for
those on treatment, 1.6% for Treatment Satisfaction and
15.2% for Treatment-related Convenience/Bother.
Based on the PCA results, the item descriptive statis-
tics, construct validity and face validity results, a total of
55 items were removed from the pilot version of the
questionnaire: 27 items were removed because more
than 70% of the patients answered “None of the time”,
“Not at all” or “Not applicable” to items; 1 item was
removed because 77% of the patients did not answer the
item; 25 items were removed according to the loading
factor analysis results; and 4 items were combined into
2 because they were highly correlated (> 0.90) and had a
similar wording ("burning” with “stinging"; “ache” with
“sore”).
Thus, the final IDEEL consists of 57 items organised
into 3 different modules. The Dry Eye Symptom-Bother
module constituted a single dimension (20 items). A 4-
point Likert scale was used for all items except “fre-
quency of experience of dry eye symptoms” that was
scored on a 5-point Likert scale. An option indicating
the symptom was not present was also available. The
Dry Eye Impact on Daily Life module was composed of
3 dimensions covering Impact on Daily Activities (9
items), Emotional Impact due to Dry Eye (12 items) and
Impact on Work due to Dry Eye (6 items); 4 individual
items and a working status item were part of the mod-
ule. A 5-point Likert scale was used for all the items
except “work status” that was scored on a dichotomous
“Yes” or “No” scale. The Dry Eye Treatment Satisfaction
module was composed of two dimensions covering
Satisfaction with Treatment Effectiveness (6 items) and
Treatment-Related Bother/Inconvenience (4 items); the
2 individuals items were part of the module. A 5-point
Likert scale was used for all the items except “eye drop
use”, that was scored on a dichotomous “Yes” or “No”
scale. The questionnaire was named IDEEL: Impact of
Dry Eye on Everyday Life. The conceptual framework of
each of the three modules of the questionnaire is
described in Figure 1, Figure 2 and Figure 3.
Scores for each dimensions ranged from 0 to 100.
Higher scores for the dimensions of the Dry Eye Impact
on Daily Life module indicated less impact on daily
activities, work and emotions; higher scores for the
Symptom-Bother dimension indicated greater bother
due to symptoms; higher scores for Satisfaction with
Treatment Effectiveness dimension indicated greater
satisfaction with treatment effectiveness; higher scores
with Treatment-related Bother/Inconvenience indicated
less treatment-related bother or inconvenience.
Item convergent validity/discriminant validity
All items of the “Emotional Impact due to Dry Eye”,
“Symptom-Bother” and “Satisfaction with Treatment
Effectiveness” met the discriminant validity criteria (each
item should correlate higher with its own dimension
than with the other dimensions).
Reliability
The internal consistency and test-retest reliability results
for the IDEEL are presented in Table 2. Internal consis-
tency reliability was good (Impact on Daily Activities,
Impact on Work; Satisfaction with Treatment Effective-
ness) to excellent (Dry Eye Symptom-Bother; Emotional
Impact). Although the Treatment-related Bother/Incon-
venience Scale only just surpassed the reliability criter-
ion with a Cronbach’s alpha of 0.70, this indicates
strong internal reliability as the scale consists of 4 fairly
heterogeneous items. All the dimensions of the IDEEL
showed good test-retest reliability, ICC ranging from
0.70 to 0.88.
Concurrent validity
Correlations between the IDEEL and SF-36 and EQ-5D
were low across the majority of dimensions (ranges:
0.04-0.45 and 0.09-0.36 respectively), as expected (Table
3). In contrast, the dimensions of the IDEEL were more
highly correlated with the items of the DEQ (range:
-0.05-0.83), indicating the concurrent validity of the
IDEEL (Table 3). The strength of the associations
between the IDEEL dimensions and DEQ items was as
expected. In general, the IDEEL dimensions were most
highly correlated with items pertaining to eye dryness
and eye discomfort. The Dry Eye Symptom-Bother mod-
ule of the IDEEL was the dimensions most highly corre-
lated with all of the DEQ items (0.21-0.83). All the
IDEEL correlations showed the lowest correlations with
the item “DEQ Watery eyes: Frequency in the past
week” (-0.05-0.21).
Known group validity
Differences between severity groups were assessed by
patient-recruited diagnosis (control, non-SS KCS and
SS), clinician report of symptoms (none, mild, moderate
and severe) and patients’ self-rating of severity ("don’t
have dry eye,”“ very mild/mild dry eye,”“ moderate dry
eye” and “severe/very severe dry eye”). For the analysis,
the very mild and mild groups were collapsed, as were
t h es e v e r ea n dv e r ys e v e r eg r o u p s .F o rt h eS a t i s f a c t i o n
with Treatment Effectiveness Scale, there was no “don’t
have dry eye” group, as patients without dry eye symp-
toms did not complete this section of the questionnaire.
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observed between different levels of severity in all the
IDEEL dimensions except Satisfaction with Treatment
Effectiveness, regardless of whether the criterion used
was recruited severity, clinician-rated severity, or
patient-rated severity (Figure 4, Figure 5 and Figure 6,
respectively). For the SF-36, significant differences
between the various severity levels were noted in the
Figure 1 Conceptual framework of the final version of IDEEL: Dry Eye Symptom-Bother module.
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severity criteria. Significant differences across severity
levels for the Mental Component Scale score were
observed only among the clinician-rated severity and
patient-reported severity. In observing the EQ-5D
results, significant differences in mean dimension scores
at the varying severity levels were also consistently
noted across all criterion measures. The Symptom-
Figure 2 Conceptual framework of the final version of IDEEL: Dry Eye Impact on Daily Life module. * One additional item about working
status introduces the items of the dimension. The item is not considered during the scoring of the IDEEL.
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Page 8 of 16Figure 3 Conceptual framework of the final version of IDEEL: Dry Eye Treatment satisfaction module.
Table 2 Internal consistency (Cronbach’s alpha) and test-retest reliability (Intraclass Correlation Coefficients, ICC)
properties of the IDEEL
Dimensions of the IDEEL Cronbach’s a coefficient (N*) ICC
(N**)
Dry Eye Symptom-Bother module*
Dry eye Symptom Bother 0.97 (209) 0.88 (167)
Dry Eye Impact module*
Impact on Daily Activities 0.86 (209) 0.77 (167)
Emotional Impact due to Dry Eye 0.94 (209) 0.83 (167)
Impact on Work Scale 0.86 (128) 0.70 (106)
Dry Eye Treatment Satisfaction module*
Satisfaction with Treatment Effectiveness 0.87 (125) 0.70 (111)
Treatment-related Bother/Inconvenience 0.70 (139) 0.80 (130)
* Number of patients who completed more than half of the items in the respective dimensions
** Number of patients for whom a score could be calculated and who were stable between the 2 visits according to the Dry Eye Change Scale (N = 167)
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as expected.
Clinical validity
Correlations between the clinical signs and the Impact
on Daily Activities, Emotional Impact due to Dry Eye,
Impact on Work due to Dry Eye, Treatment-related
Bother/Inconvenience and Symptom-related Bother
dimensions of the IDEEL were low and statistically sig-
nificant (p < 0.05) for most of them except between
Snellen visual acuity, bulbar redness and fluorescein
break-up time and the Work dimension (Table 4). The
Symptom-related Bother and Treatment-related
Bother/Inconvenience dimensions had the highest cor-
relation with clinical signs overall (up to 0.37) while
the Satisfaction with Treatment Effectiveness scale did
not correlate significantly with any of the clinical signs
(Table 4).
Discussion
Many studies have shown that dry eye signs poorly cor-
relate well with symptoms, although late day symptoms
show moderate correlations with some signs [13] and
composite scores including both signs and symptoms
may improve diagnosis of the condition [18]. This sug-
gests a need for more emphasis on PRO in dry eye in
order to fully assess the condition and effect of treat-
ments [3,50]. Existing PRO instruments focus on the
ability to identify and diagnose dry eye, assess the preva-
lence of the condition, and assess the severity and fre-
quency of symptoms. With novel treatments under
development, the need evolved for an instrument to
a s s e s st h ei m p a c to fc h a n g ei nt h ed r ye y ec o n d i t i o n .
From a clinician’s perspective, this will help in setting
realistic expectations and in measuring the degree of
improvement in individual patients and the remaining
issues. From a regulatory perspective, such an
Table 3 Concurrent validity of the IDEEL with the SF-36, EQ-5D and Dry Eye Questionnaire (Pearson coefficient
correlations)
Questionnaires Modules of the IDEEL
Dry Eye
Symptom-
Bother*
Dry Eye Impact on Daily Life Dry Eye Treatment Satisfaction
Impact on
Daily
Activities*
Emotional Impact
due to Dry Eye*
Impact on Work
due to Dry Eye*
Satisfaction with
Treatment
Effectiveness*
Treatment-
related Bother/
Inconvenience*
Short Form-36
Physical Functioning -0.33 0.30 0.35 0.04 0.06 0.35
Role Physical -0.35 0.30 0.36 0.24 0.15 0.37
Bodily Pain -0.39 0.34 0.39 0.22 0.14 0.31
Vitality Index -0.36 0.34 0.40 0.31 0.24 0.38
General Health
Perceptions
-0.38 0.32 0.45 0.18 0.17 0.40
Social Functioning -0.31 0.31 0.40 0.27 0.11 0.35
Role Emotional -0.27 0.29 0.33 0.20 0.12 0.29
Mental Health Index -0.32 0.33 0.40 0.13 0.30 0.27
Physical Component
Scale
-0.37 0.31 0.38 0.16 0.09 0.37
Mental Component
Scale
-0.26 0.29 0.36 0.23 0.23 0.26
EuroQol-5D
EQ-5D Quality of Life
Score
-0.36 0.31 0.35 0.24 0.23 0.30
EQ-5D VAS Health
Thermometer
-0.34 0.30 0.35 0.22 0.09 0.22
Dry Eye Questionnaire
All items (correlation
min; correlation max)
0.21; 0.83 -0.19; -0.65 -0.11; -0.69 -0.07; -0.68 -0.05; -0.48 -0.06; -0.60
* Number of patients ranging from 203 to 209 for Dry Eye Symptom-Bother, Impact on Daily Activities and Emotional Impact due to Dry Eye; ranging from 130
to 131 for Impact on Work due to Dry Eye; ranging from 131 to 137 for Satisfaction with Treatment Effectiveness; ranging form 148 to 154 for Treatment
-Related Bother/Inconvenience
Bold font correlations are the highest correlations between the IDEEL scales and the SF-36 or EQ-5D scales.
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Page 10 of 16instrument will allow a standardised method to assess
treatment effectiveness in primarily symptom-based con-
ditions such as dry eye so that claims can be supported
with evidence in the form of PRO.
Despite being developed prior to the FDA PRO gui-
dance, the IDEEL instrument was developed in accor-
dance with standards outlined [51], which requires
demonstration of content validity and saturation. The
IDEEL was developed based on patient input and is the
first dry eye PRO questionnaire to formally demonstrate
saturation of relevant concepts, therefore supporting its
content validity. The SS patients were quicker to express
the detrimental impacts dry eye had on every aspect of
their lives when compared to non-SS KCS patients dur-
ing the focus group discussions, however saturation was
achieved on the overall population. To further support
content validity, when decisions were made to delete
items, psychometrics and the clinicians’ and patients’
own opinions were considered. Multi-Trait and PCA
analyses confirmed the hypothesised structure of the
IDEEL as 3 distinct modules. The final IDEEL comprises
57 items organised into 3 modules, Dry Eye Symptom-
Bother, Dry Eye Impact on Daily Life, and Dry Eye
Treatment Satisfaction, that allow a comprehensive eva-
luation of the burden of the dry eye condition on
patients. The assumption about the pre-defined
structure of the IDEEL as 3 distinct modules and the
lack of data from PCA and Multi-trait analyses on the
questionnaire as a whole could be raised as limitations,
as the purpose of these analyses is to allow the defini-
tion of the structure and organisation of the instrument.
However, satisfaction, which is defined as an emotive
evaluation which enables the assessment of the appro-
priateness of the perceived quality of treatment with
expectations [52], is conceptually different from HRQL,
that covers physical, psychological, social functioning,
and somatic sensations [47]. Similarly, it is now
acknowledged that symptoms are a PRO distinct from
HRQL [49]. In light of these definitions, our assumption
appears to be legitimate.
Psychometrically, the IDEEL final dimensions are reli-
able and valid. In particular, when comparing results to
the SF-36 and EQ-5D, the IDEEL consistently outper-
formed these generic measures in distinguishing
between patients’ reported severity, clinician-rated sever-
ity and patient-rated severity groups, as one would
expect with a condition-specific scale (data not shown)
[20]. The generic measures appear capable of distin-
guishing between more severe categories of patients (i.e.,
moderate versus severe), but not capable of distinguish-
ing between mild and moderate levels. In contrast, the
IDEEL dimensions are able to distinguish between the
Figure 4 Known group validity of the IDEEL, SF-36 and EQ-5D dimensions by patient-recruited severity of the diagnosis. Non-SS KCS =
non-Sjögren keratoconjunctivitis sicca; SS = Sjögren Syndrome; IDEEL, Impact of Dry Eye on Everyday Life; SF-36, Short-Form-36; EuroQoL-5D, EQ-
5D; Symptom, Symptom-Bother dimension; ADL, Impact on Daily Activities dimension; Emotional, Emotional Impact due to Dry Eye dimension;
Work, Impact on Work due to Dry Eye dimension; Effectiveness, Satisfaction with treatment effectiveness dimension; Treatment bother,
Treatment-related bother/inconvenience dimension; PCS, Physical Component Scale; MCS, Mental Component Scale; Index, EQ-5D items (score
ranges from 0 to 1); VAS, Visual Analogue Scale.
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Page 11 of 16majority of severity levels, with the exception of the
Treatment-related Satisfaction module; however treat-
ment satisfaction might not be expected to differ by
severity of condition alone. One might be surprised with
the low correlation level between some of the IDEEL
dimensions and the SF-36 (such as “impact on work” of
IDEEL and “role physical” of SF-36; “emotional impact”
of IDEEL and the mental component (or some of the
related scales) SF-36). The SF-36 role-physical items
focus on impact due to their ‘physical health. We believe
that when people respond, they interpret ‘physical
health’ to mean a disease or bodily impairments (e.g.
torso, limbs) and probably do not think of dry eye as a
‘disease’ nor think of the eye as being ‘bodily’.F u r t h e r
cognitive debriefing of SF-36 would be required to con-
firmed or not this hypothesis.
In our testing across known diagnostic groups,
results were fairly consistent across methods of defin-
ing severity (self-assessment, clinician assessment, or
recruited diagnosis). Given the relative lack of clarity
in the field on how to define dry eye severity precisely,
we used these methods to define severity. We would
recommend using this type of approach in any tests of
known groups or clinical validity, since the use of
insensitive or non-specific clinical criteria that do not
relate to symptoms could result in concluding that a
questionnaire is not discriminative or responsive, when
in reality it is the clinical criterion used to define
severity that is not discriminative or responsive. This
issue is particularly important in dry eye because no
single clinical measure is widely accepted as the ‘gold
standard’ in predicting dry eye symptoms and the
impact of dry eye on patients’ quality of life, [53]
although recent evidence by Sullivan, Lemp and cow-
orkers suggests that tear film hyperosmolarity may cor-
relate better than other clinical tests for the condition
[18,54]. Because clinical judgments remain central in
the assessment of dry eye severity, the same team has
proposed the use of composite severity index associat-
ing osmolarity testing with traditional tests of the tra-
ditional clinical tests in order to classify dry eye
severity as accurately as possible [18]. The likelihood
that dry eye symptoms stem from a number of aetiolo-
gies also confounds the effort to start the diagnostic
process from the signs rather than the symptoms.
Determining that the patient is experiencing sufficient
symptoms to warrant further diagnosis and treatment
is a more effective clinical starting point for such a
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Figure 5 Known group validity of the IDEEL, SF-36 and EQ-5D dimensions by clinician-rated severity.I D E E L ,I m p a c to fD r yE y eo n
Everyday Life; SF-36, Short-Form-36; EuroQoL-5D, EQ-5D; Symptom, Symptom-Bother dimension; ADL, Impact on Daily Activities dimension;
Emotional, Emotional Impact due to Dry Eye dimension; Work, Impact on Work due to Dry Eye dimension; Effectiveness, Satisfaction with
treatment effectiveness dimension; Treatment bother, Treatment-related bother/inconvenience dimension; PCS, Physical Component Scale; MCS,
Mental Component Scale; Index, EQ-5D items (score ranges from 0 to 1); VAS, Visual Analogue Scale.
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Page 12 of 16complex condition. Hence the importance of using a
PRO instrument such as the IDEEL in conjunction
with the clinical tests to properly assess the improve-
ment of patients’ dry eye condition.
Further development work is ongoing to allow the use
of the IDEEL as an estimate of the overall health impact
of dry eye and improvement by treatment. A recent
study established the minimal clinically important
0
10
20
30
40
50
60
70
80
90
100
Symptom (p<0.0001)
ADL (p<0.0001)
Emotional (p<0.0001)
Work (p<0.0001)
Effectiveness (p=0.0010)
Treatment bother (p<0.0001)
PCS (p<0.0001)
MCS (p=0.0086)
Index (p<0.0001)
VAS (p<0.0001)
M
e
a
n
 
+
/
-
 
S
T
D
m
Don't have dry eye
Very mild/mild
Moderate
Severe/very severe
Figure 6 Known group validity of the IDEEL, SF-36 and EQ-5D dimensions by patient-rated severity. IDEEL, Impact of Dry Eye on
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Emotional, Emotional Impact due to Dry Eye dimension; Work, Impact on Work due to Dry Eye dimension; Effectiveness, Satisfaction with
treatment effectiveness dimension; Treatment bother, Treatment-related bother/inconvenience dimension; PCS, Physical Component Scale; MCS,
Mental Component Scale; Index, EQ-5D items (score ranges from 0 to 1); VAS, Visual Analogue Scale.
Table 4 Clinical validity of the IDEEL (Pearson correlation coefficients)
Clinical tests IDEEL Modules
Dry Eye
Symptom-
Bother*
Impact Daily Life Dry Eye Treatment Satisfaction
Impact on
Daily
Activities*
Emotional Impact
due to Dry Eye*
Impact on Work
due to Dry Eye*
Satisfaction with
Treatment-
Effectiveness*
Treatment-
related Bother/
Inconvenience*
Snellen visual acuity 0.22** -0.25** -0.24** -0.09 -0.07 -0.25**
Bulbar redness 0.18** -0.15** -0.22** -0.18 0.01 -0.25**
Schirmer 1 tear test
(mm)
-0.30** 0.14** 0.24** 0.11 0.09 0.37**
Fluorescein break up
time (sec)
-0.22** 0.17** 0.20** 0.22** 0.01 0.28**
Overall corneal
fluorescein staining
rating
0.31** -0.21** -0.25** -0.30** 0.06 -0.32**
Conjunctival lissamine
green staining rating
0.30** -0.17** -0.25** -0.29** 0.03 -0.31**
* Number of patients ranging from 206 to 209 for Dry Eye Symptom-Bother, Impact on Daily Activities and Emotional Impact due to Dry Eye; ranging from 129
to 131 for Impact on Work due to Dry Eye; ranging from 135 to 137 for Satisfaction with Treatment Effectiveness; ranging form 151 to 154 for Treatment
-Related Bother/Inconvenience
** p < 0.05
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Page 13 of 16difference of the IDEEL dry eye Symptoms-Bother
dimension in mild, moderate and severe dry eye [32]. A
12-point shift in the IDEEL Dry Eye Symptom-Bother
dimension score was determined to be the clinical
important difference relating to a global change in dry
eye condition after implementing tear replacement
drops [32]. Research in assessing the overall dry eye
health burden on the patients is ongoing, including its
comparison to other diseases, and highlights the impact
of dry eye condition in patients in terms of utilities out-
comes [55].
The focus groups in the development and in the vali-
dation of the IDEEL included US and Canadian patients.
A tt h es a m et i m ei nE u r o p e ,aP R Oi n s t r u m e n t ,t h e
Ocular Surface Disease (OSD), was being developed
based on French dry eye patients’ outcomes. Similar
concepts and sub-concepts were identified from this
study, supporting the validity of the concepts that had
emerged from the focus groups, as well as the appropri-
ateness of the items to European patients [56,57]. It is
likely that in other parts of the world, no different issues
associated with dry eye will emerge, but this should be
verified before being implemented in a study. The use
of the IDEEL in Europe is made possible given the avail-
ability of linguistically validated translations in the dif-
ferent European languages. So far, currently validated or
in development languages include German, Spain,
French for France, English for UK, Polish, Italian Portu-
guese (Brazil), Simplified Chinese (Singapore), and Span-
ish for US.
The use of the IDEEL in other different studies will
continue to provide further data to obtain further infor-
mation on the importance of specific items for specific
dry eye patients with different aetiologies. It may also
allow the further reduction of items, while ensuring all
the important concepts to patients are evaluated, in case
of developing a briefer instrument for use in clinical
practice. The items of the IDEEL are likely to be appro-
priate for specific sub-groups of dry eye patients; due to
the similarity of the symptom-bother and daily life
impact reported by patients with meibomian gland dys-
function (data not shown) [58]. However, to ensure all
issues of relevance in this condition are covered, future
studies and saturation assessment would be required.
In conclusion, the IDEEL is a reliable and valid ques-
tionnaire relevant to the issues that are specific to dry
eye patients and it meets the FDA PRO guidelines. The
IDEEL is the only comprehensive instrument that was
designed to assess the entire gamut of the impact of dry
eye on patient outcomes: domains of patients’ everyday
life, treatment satisfaction, and amount of bother by
symptoms. IDEEL will aid in the assessment of DE
symptom severity and impact, and will complement
information gathered through traditional clinical exams
and measures. The continued use of the IDEEL instru-
ment, either as a whole or as specific modules, will pro-
vide assessment of the impact of dry eye on patient dry
eye-related quality of life that may aid treatment selec-
tion and dry eye management in clinical practices.
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